Abstract
In this article (Clin Cancer Res 2010;16:2205–13), which was published in the April 1, 2010, issue of Clinical Cancer Research (1), there was an error in the labeling of Fig 2. The corrected figure appears below. The online article has been changed to reflect this correction and no longer matches the print.
Fig. 2.
Progression-free survival and overall survival by KRAS status (KRAS efficacy sets, central assessment). The proportion of patients with progression-free survival (top) and overall survival (bottom) over time (wk) are shown for patients in the Low/Negative EGFR study (left) and the High EGFR study (right). Vertical bars, censored observation.
This OnlineFirst version was published on May 11, 2010
doi: 10.1158/1078-0432.CCR-10-0766
Correction: Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
Jump to section
Advertisement